Nutriband Inc.'s Path to Commercialization of AVERSA Fentanyl: Key FAQs

What is AVERSA Fentanyl?

AVERSA Fentanyl is poised to become the world’s first opioid pain patch with abuse deterrent properties, as stated by Nutriband’s CEO in a recent report.

Who is Nutriband partnering with for the development of AVERSA Fentanyl?

Nutriband has formalized a strong product-development partnership and long-term commitment with Kindeva Drug Delivery for the development of AVERSA Fentanyl.

What are Nutriband’s key steps towards commercialization?

Nutriband is focused on developing and scaling up the manufacturing process of AVERSA technology, in collaboration with Kindeva Drug Delivery, to bring it closer to commercialization.

Where can I find more updates about Nutriband Inc.?

The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB.

Why is the development of AVERSA Fentanyl significant?

The development of AVERSA Fentanyl is significant as it introduces the first opioid pain patch with abuse deterrent properties, addressing a critical need in pain management and drug abuse prevention.

How does Nutriband plan to achieve its 2025 expectations?

Nutriband plans to achieve its 2025 expectations by advancing the commercialization of AVERSA technology through its partnership with Kindeva Drug Delivery and scaling up the manufacturing process.

What is the role of Kindeva Drug Delivery in this partnership?

Kindeva Drug Delivery, a leading global contract development and manufacturing organization, is working with Nutriband to develop AVERSA Fentanyl, focusing on drug-device combination products.

Where can I read more about Nutriband’s recent achievements?

You can read more about Nutriband’s recent achievements and milestones in the CEO’s report to shareholders at https://ibn.fm/9K5zT.